Commonly employed concentrations of CPT1α inhibitors have been shown to elicit severe oxidative stress (Jiang et al., 2022), which, along with the associated inflammation, are pivotal factors that expedite the progression from steatosis to more advanced conditions such as MASH or MAFLD (Du et al., 2019). This evidence concerns the gene CPT1A and steatosis.